- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05688085
Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers
August 15, 2023 updated by: Handok Inc.
A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of Irbesartan High/Amlodipine Fixed Dose Combination in Comparison With Co-administration of Mono Compounds in Healthy Volunteers
The purpose of this study is to compare pharmacokinetics and safety of Irbesartan High and Amlodipine Fixed Dose Combination and coadministration of mono compounds in healthy adult volunteers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 08779
- H plus Yangji Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Patients who are 19 years or older on screening
- Signed informed consent
- Healthy Volunteer
- Other inclusion applied
Exclusion Criteria:
- Clinically relevant/significant findings as evaluated by the investigator
- Other exclusion applied
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Irbesartan High/Amlodipine Fixed dose combination
participants will receive one tablet of Irbesartan High/Amlodipine FDC in a crossover design
|
Irbesartan High/Amlodipine FDC
|
Experimental: Co-administration of Irbesartan High and Amlodipine
participants will receive one table each of Irbesartan High and Amlodipine in a crossover design
|
Co-administration of Irbesartan High and Amlodipine
Co-administration of Irbesartan High and Amlodipine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCt of Irbesartan High and Amlodipine
Time Frame: 72 hours
|
72 hours
|
Cmax of Irbesartan High and Amlodipine
Time Frame: 72 hours
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCinf of Irbesartan High and Amlodipine
Time Frame: 72 hours
|
72 hours
|
AUCt/AUCinf of Irbesartan High and Amlodipine
Time Frame: 72 hours
|
72 hours
|
tmax of Irbesartan High and Amlodipine
Time Frame: 72 hours
|
72 hours
|
half-life of Irbesartan High and Amlodipine
Time Frame: 72 hours
|
72 hours
|
CL/F of Irbesartan High and Amlodipine
Time Frame: 72 hours
|
72 hours
|
Vz/F of Irbesartan High and Amlodipine
Time Frame: 72 hours
|
72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 18, 2022
Primary Completion (Actual)
December 29, 2022
Study Completion (Actual)
April 21, 2023
Study Registration Dates
First Submitted
January 8, 2023
First Submitted That Met QC Criteria
January 8, 2023
First Posted (Actual)
January 18, 2023
Study Record Updates
Last Update Posted (Actual)
August 18, 2023
Last Update Submitted That Met QC Criteria
August 15, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Amlodipine
- Irbesartan
Other Study ID Numbers
- HD-AI-103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Irbesartan High/Amlodipine FDC
-
Handok Inc.CompletedHealthy VolunteersKorea, Republic of
-
SanofiCompleted
-
Handok Inc.CompletedEssential HypertensionKorea, Republic of
-
Handok Inc.CompletedHealthy VolunteersKorea, Republic of
-
SanofiCompletedHypertensionIndia, Philippines, Taiwan, Korea, Republic of
-
SanofiCompletedIrbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy (I-ADD)HypertensionMorocco, Brazil, Colombia, Guatemala, Mexico, Tunisia, United Arab Emirates, Venezuela
-
SanofiCompletedHypertensionBrazil, Chile, Colombia, Egypt, Lebanon, Mexico, Morocco, Tunisia, Venezuela
-
Handok Inc.CompletedEssential HypertensionKorea, Republic of
-
Handok Inc.CompletedEssential HypertensionKorea, Republic of
-
GlaxoSmithKlineCompleted